Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20509035
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\20509035
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Amino+Acids
2011 ; 41
(4
): 893-9
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
S100P: a novel therapeutic target for cancer
#MMPMID20509035
Arumugam T
; Logsdon CD
Amino Acids
2011[Oct]; 41
(4
): 893-9
PMID20509035
show ga
S100P expression is described in many different cancers, and its expression is
associated with drug resistance, metastasis, and poor clinical outcome. S100P is
member of the S100 family of small calcium-binding proteins that have been
reported to have either intracellular or extracellular functions, or both.
Extracellular S100P can bind with the receptor for advanced glycation end
products (RAGE) and activate cellular signaling. Through RAGE, S100P has been
shown to mediate tumor growth, drug resistance, and metastasis. S100P is
specifically expressed in cancer cells in the adult. Therefore, S100P is a useful
marker for differentiating cancer cells from normal cells, and can aid in the
diagnosis of cancer by cytological examination. The expression of S100P in cancer
cells has been related to hypomethylation of the gene. Multiple studies have
confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and
different blockers are being developed including small molecules and antagonist
peptides. This review summarizes the role and significance of S100P in different
cancers.
free
free
free
